Affordable Access

deepdyve-link
Publisher Website

Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance.

Authors
  • Mahal, Amandeep R1, 2
  • Mahal, Brandon A3
  • Nguyen, Paul L4
  • Yu, James B1, 2, 5, 6
  • 1 Yale School of Medicine, Yale University, New Haven, Connecticut.
  • 2 Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale, Yale University, New Haven, Connecticut.
  • 3 Harvard Radiation Oncology Program, Harvard University, Boston, Massachusetts.
  • 4 Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • 5 Yale Cancer Center, Yale University, New Haven, Connecticut.
  • 6 Department of Therapeutic Radiology, Yale School of Medicine, Yale University, New Haven, Connecticut.
Type
Published Article
Journal
Cancer
Publisher
Wiley (John Wiley & Sons)
Publication Date
Feb 15, 2018
Volume
124
Issue
4
Pages
752–759
Identifiers
DOI: 10.1002/cncr.31106
PMID: 29084350
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

In the current national debate regarding private insurance versus Medicaid expansion, understanding how insurance is associated with racial disparities in prostate cancer (CaP) outcomes has broad policy implications. In the current study, the authors examined the association between insurance status, race, and CaP outcomes. The Surveillance, Epidemiology, and End Results program identified 155,524 men aged < 65 years who were diagnosed with CaP from 2007 through 2014. The association between insurance and stage of disease at the time of presentation was examined. Among men with localized CaP, the associations between insurance and receipt of therapy and prostate cancer-specific mortality (PCSM) were determined. Compared with private insurance, men with Medicaid were more likely to present with metastatic disease (adjusted odds ratio [AOR], 4.27; 95% confidence interval [95% CI], 4.01-4.55), were less likely to receive definitive treatment (AOR, 0.67; 95% CI, 0.62-0.71), and had increased PCSM (adjusted hazard ratio, 1.83; 95% CI, 1.50-2.24), regardless of race. Significant interactions between race and insurance status indicated that insurance had more than an additive association with race. Among privately insured patients, disparities in PCSM (AOR, 1.2; 95% CI, 1.03-1.40 [P = .019]) and presentation with metastatic disease (AOR, 1.13; 95% CI, 1.06-1.21 [P<.001]) were observed. No disparities were observed among patients with Medicaid insurance with regard to PCSM (AOR, 0.79; 95% CI, 0.52-1.20 [P = .272]) and metastatic disease (AOR, 0.91; 95% CI, 0.80-1.03 [P = .139]). Racial disparities in the outcomes of patients with CaP were observed in privately insured cohorts, whereas these disparities appeared to be reduced among patients with Medicaid insurance. However, outcomes need to be improved overall. Whether the equality in outcomes for Medicaid is due to white and African American patients doing "equally poorly" or "equally well" is unclear. Cancer 2018;124:752-9. © 2017 American Cancer Society. © 2017 American Cancer Society.

Report this publication

Statistics

Seen <100 times